(VIANEWS) - Shares of BIOCARTIS (BEL 20: BCART.BR) dropped by a staggering 34.03% in 21 sessions from €0.58 to €0.38 at 05:13 EST on Wednesday, after five successive sessions in a row of losses. BEL 20 is sliding 0.34% to €3,584.67, after four successive sessions in a row of losses.
About BIOCARTIS
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Earnings Per Share
As for profitability, BIOCARTIS has a trailing twelve months EPS of €-0.8.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOCARTIS's stock is considered to be overbought (>=80).
Volume
Today's last reported volume for BIOCARTIS is 345373 which is 1.14% above its average volume of 170549.
More news about BIOCARTIS (BCART.BR).